ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“Improved overall survival was observed with gotistobart, a novel anti-CTLA-4 antibody, versus docetaxel in stage 1 of the PRESERVE-003 Clinical Trial in patients with squamous NSCLC who progressed on anti-PD-(L)1 therapy.
A chemotherapy-free option is much needed in this setting, where therapeutic choices are currently limited.
Catch up on the latest news from ELCC 2026 in the ESMO Daily Reporter.”
Other articles about ELCC 2026 on OncoDaily.